Abstract
The diagnosis and management of diabetic neuropathy can be a major challenge. Late diagnosis contributes to significant morbidity in the form of painful diabetic neuropathy, foot ulceration, amputation, and increased mortality. Both hyperglycaemia and cardiovascular risk factors are implicated in the development of somatic and autonomic neuropathy and an improvement in these risk factors can reduce their rate of development and progression. There are currently no US Food and Drug Administration (FDA)-approved disease-modifying treatments for either somatic or autonomic neuropathy, as a consequence of multiple failed phase III clinical trials. While this may be partly attributed to premature translation, there are major shortcomings in trial design and outcome measures. There are a limited number of partially effective FDA-approved treatments for the symptomatic relief of painful diabetic neuropathy and autonomic neuropathy.
Keywords: diabetic neuropathy, autonomic neuropathy, diagnosis, treatment
Introduction
Diabetic peripheral neuropathy (DPN) occurs as a consequence of damage to the sensory, autonomic and motor nerves and can present with diverse symptoms and deficits (Table 1). The commonest presentations are those of somatic and autonomic neuropathy, and early diagnosis of these subtypes is recommended.1 Small-fibre neuropathy can develop in patients with impaired glucose tolerance (IGT),2 particularly those who develop type 2 diabetes mellitus (T2DM)3 and it is recommended that patients with peripheral neuropathy should be evaluated for glucose dysmetabolism. However, the methods currently advocated to diagnose DPN, for example, neurological exam, monofilament and vibration sensation, detect moderate-to-severe large-fibre neuropathy, missing early small-fibre neuropathy.4 Other causes of neuropathy, including B12 deficiency, and inflammatory neuropathies must be actively sought, as they are potentially treatable.5,6 It is generally held that motor problems arise late in diabetic neuropathy, however recent studies show reduced muscle strength, volume and altered gait in patients with IGT and T2DM.7–9 Furthermore, acute-onset severe pain and swelling in a proximal muscle, should also alert the physician to the occurrence of diabetic muscle infarction.10 There is a threefold to fivefold higher prevalence of cranial11 and peripheral mononeuropathies in patients with diabetes. Carpal tunnel syndrome is the commonest mononeuropathy in patients with diabetes12 due to increased microangiopathy and vascular endothelial growth factor expression.13,14 While bracing and splinting relieve pain, carpal tunnel decompression surgery outcomes are excellent and associated with recovery of neurophysiological function in patients with diabetes.15
Table 1.
Diabetic sensorimotor polyneuropathy |
---|
Predominantly small-fibre neuropathy Predominantly large-fibre neuropathy Mixed small and large-fibre neuropathy (commonest) |
Atypical neuropathy |
Isolated cranial neuropathy (III, IV, VI, VII) Mononeuropathy (ulnar, median, peroneal) Radiculopathy Lumbosacral radiculoplexus neuropathy (amyotrophy) Cervical/thoracic radiculopathy Motor neuropathy Reduced muscle volume and strength Muscle infarction |
Disease-modifying therapies for DPN
Improved glycaemic control can prevent the progression of diabetic neuropathy in T1DM, but not in T2DM.16 This surprising result may be attributed to late and less effective lowering of glucose in patients with T2DM and established neuropathy, concomitant weight gain and hypoglycaemia, and the use of insensitive endpoints.17,18 Most of the studies assessing the effect of improved glycaemic control on neuropathy in T2DM were neither powered nor designed to show a benefit on neuropathy.16 Cardiovascular risk factors, especially hypertension and triglycerides have been shown to play an important role in the development of diabetic neuropathy.19 The STENO-2 study showed the overwhelming benefit of multifactorial risk factor reduction on cardiovascular outcomes,20 mortality,21 retinopathy, nephropathy and autonomic neuropathy, but not somatic neuropathy, as vibration perception was the endpoint for assessing neuropathy.22 Indeed, a recent Japanese study has shown that intensive multifactorial intervention which led to an almost normalization of glycosylated haemoglobin (HbA1c) with weight loss and a reduction in blood pressure showed a significant improvement in neurophysiology and small-nerve-fibre repair, assessed using corneal confocal microscopy,23 echoing the results of a previous study.24 Early diagnosis and intervention may also be the key, as lifestyle intervention in patients with prediabetes improved sudomotor function and intraepidermal nerve-fibre density.25 Indeed, smaller studies which have utilized more rigorous endpoints have shown a significant benefit on neurophysiology after treatment with an angiotensin-converting enzyme (ACE) inhibitor26 and on neurological deficits and neurophysiology after treatment with an ACE inhibitor and calcium-channel blocker.27 Statins or fibrates can also prevent the development of DPN,28,29 reduce diabetic foot infection,30 lower-extremity amputation31,32 and increase healing of foot ulcers.33 A post hoc analysis of the LEADER (Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results) study has shown that the glucagon-like peptide-1 (GLP-1) receptor agonist liraglutide reduced ulcer-related foot amputation.34 There are compelling experimental data showing a direct benefit of GLP-1 agonists on neuropathy.35–37 This would suggest that the GLP-1 agonists may have potential benefits in the treatment of diabetic neuropathy35 and a randomized clinical trial with rigorous endpoints is required to show this. The lack of rigorous and sensitive endpoints,4 recruitment of patients with a broad spectrum of neuropathy severity and short trial durations have contributed to the failure of clinical trials in DPN.17 Accurate phenotyping to select and stratify patients using sensitive endpoints targeting small-fibre repair (corneal confocal microscopy, skin biopsy) may allow trials of shorter duration to show an initial therapeutic effect. This would provide pharmaceutical companies with a go–no–go signal to invest in larger and longer trials, to gain US Food and Drug Administration (FDA) approval of disease-modifying therapies for DPN.18
Painful diabetic neuropathy
Painful diabetic neuropathy (PDN), a manifestation of small-fibre damage38–40 is characterized by burning pain and significantly impacts on the patient’s quality of life,41–43 due to associated depression, anxiety and sleep disturbance.42 It can affect 14.0−65.3% of patients with diabetes,41,44–49 and the broad prevalence rates are attributed to different populations, risk factors and diagnostic methods. Paradoxically, the prevalence of painful symptoms may be higher in south Asians, despite a lower overall prevalence of neuropathy50 and small-fibre neuropathy.51 Despite the availability of a number of questionnaires, for example, the Douleur Neuropathique 4 (DN4) questionnaire,52 Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) pain scale53 and Neuropathic Pain Questionnaire (NPQ),54 a large proportion of patients with PDN remain undiagnosed,55,56 and ‘suffer in silence’.57 The risk factors for painful diabetic neuropathy include older age, duration of diabetes, presence of diabetic peripheral neuropathy,41,44–46,48 obesity,41,45,56,58 smoking,44,58 poor glycaemic control,59,60 low high-density lipoprotein (HDL) cholesterol,41 elevated low-density lipoprotein (LDL) cholesterol, triglycerides and creatinine, 47 and vitamin D deficiency.61,62
Treatment of PDN
There is no evidence that improvement in glycemic control improves PDN; indeed, the opposite is true, where rapid and large reductions in HbA1c may precipitate an acute painful neuropathy.63 The treatment of PDN has relied on trying different moderately effective therapies until one works, with minimal side effects. However, improved genotyping64,65 and clinical phenotyping66 may allow targeted mechanism-based therapies. Identifying patients with an irritable nociceptor can reduce the number needed to treat (NNT) for oxcarbazepine to 3.9 compared with 6.9 in patients with the nonirritable nociceptor.67 Similarly, identifying patients with altered rate-dependent depression (RDD), a marker of descending inhibitory pathway dysfunction, may focus on those who will respond optimally to selective norepinephrine-reuptake inhibitors, for example, duloxetine.68
Tricyclic antidepressants (TCAs) mediate analgesic efficacy by indirectly modifying the opioid system in the brain and via neuromodulation of serotonin and noradrenaline.69–71 A systematic review of 17 studies involving amitriptyline in 1342 participants in PDN trials showed moderate efficacy and caution, as there was a high risk of bias due to the small participant numbers in each study.72 Duloxetine and venlafaxine potentiate the descending inhibitory pathways,73 and a Cochrane review of eight randomized controlled trials (RCTs) with 2728 participants showed that duloxetine 60 mg daily had an NNT of five.74 Although gabapentin is not FDA approved for the treatment of PDN, a recent Cochrane review has shown efficacy of this medication in DPN and it is widely prescribed. However, somnolence and dizziness limit dose titration and most patients do not receive the doses (1200−3600 mg) that have been shown to be efficacious.75 Pregabalin is FDA approved for PDN, based on a number of RCTs.76–78 Mirogabalin has recently shown efficacy and good tolerability in a phase II and two phase III clinical trials in DPN.79–81 Tramadol may also be used second line, but a Cochrane review found that the efficacy of tramadol was determined in small inadequate-sized studies, with a risk of bias.82 Tapentadol extended release is only the third medication to be recommended by the FDA for PDN.83–86 The COMBO-DN study showed comparable neuropathic pain outcomes between a combination of duloxetine 60 mg daily and pregabalin 300 mg daily, compared with high-dose monotherapy of either duloxetine 120 mg daily or pregabalin 600 mg daily.87 Furthermore, in an exploratory post hoc analysis, high-dose monotherapy was more favourable in patients with severe pain, whereas combination therapy was more beneficial in patients with mild-to-moderate pain.88 There are few head-to-head studies comparing different drugs, but in a double-blind RCT in patients with PDN, analgesic efficacy was comparable between amitriptyline, duloxetine and pregabalin.89 We have recently shown that treatment with vitamin D improves the severity of neuropathic pain90 and quality of life in patients with PDN.91
Autonomic neuropathy
Autonomic neuropathy is characterized by a range of symptoms and signs, which can be debilitating in a minority of patients, especially females with T1DM (Table 2). Cardiac autonomic neuropathy (CAN) per se is the strongest risk factor for all-cause mortality in T1DM and was an independent risk factor for mortality in the ACCORD study of patients with T2DM.92,93 Hence, screening for CAN is recommended at diagnosis in T2DM and after 5 years in T1DM.1 The diagnosis of CAN includes documentation of the symptoms and signs, although there is a weak correlation between symptoms and autonomic deficits.94,95 Cardiovascular autonomic reflex testing (CARTs) includes heart rate response to deep breathing, standing and the Valsalva manoeuvre.96
Table 2.
Cardiac autonomic neuropathy
Resting tachycardia and/or fixed HR Nondipping of nocturnal systolic BP Orthostatic hypotension Exercise intolerance Syncope and light headedness Painless myocardial infarction Arrhythmias Sudomotor neuropathy Anhidrosis Gustatory sweating Urogenital autonomic neuropathy Bladder dysfunction (1) Nocturnal frequency and urgency (2) Urinary hesitancy, weak stream, dribbling and urinary incontinence Sexual dysfunction Male: erectile dysfunction, decreased libido and retrograde ejaculation Female: decreased sexual desire and arousal, inadequate lubrication Gastrointestinal autonomic neuropathy Nausea/vomiting Bloating with inability to eat a full meal Increased variability in blood sugar and hypos Nocturnal diarrhoea |
BP, blood pressure; HR, heart rate.
Disease-modifying therapies for autonomic neuropathy
The DCCT showed that intensive glycaemic control in patients with T1DM reduced the development of CAN by 45%97 and the STENO-2 trial showed that intensified multifactorial treatment in patients with type 2 diabetes reduced the risk of CAN progression by 68%.98,99 A small early study found favourable effects of alpha-lipoic acid (ALA) on CAN,100 but a more recent study of triple antioxidant therapy (allopurinol, ALA and nicotinamide) showed no benefit.101 There are currently no FDA-approved disease-modifying treatments for CAN.
Orthostatic hypotension
Symptoms of orthostatic hypotension (OH) occur on standing and include light headedness, weakness, giddiness and syncope. OH is defined as a blood pressure fall on standing >20/10 mmHg (>30/15 mmHg in those with BP > 150/90 mmHg) without an increase in heart rate (<15 beats per minute).102 Treatment of OH involves fluid and salt repletion and encouragement of physical activity and exercise to avoid deconditioning.103,104 Fludrocortisone is used but is not FDA approved for OH, and there are concerns over supine hypertension, hypokalaemia, congestive cardiac failure and peripheral oedema.105 Both midodrine and droxidopa are approved by the FDA for the treatment of symptomatic neurogenic OH.106
Gastroparesis
Gastroparesis may present with bloating, nausea and overt recurrent vomiting, necessitating admission to hospital, or may underlie unexplained variability in blood sugars. It is defined as the delayed removal of stomach contents in the absence of a physical obstruction.107 Gastric emptying should be formally assessed at 15-min intervals, with scintigraphy 4 h after food intake of digestible solids. Metoclopramide is the only FDA-approved drug for the treatment of gastroparesis, but limited efficacy and the risk of tardive dyskinesia has led the FDA and European Medicines agency to limit its use to a maximum of 5 days. New therapies currently being investigated include motilin-receptor agonists, ghrelin-receptor agonists, and neurokinin-receptor antagonists. Mechanical options for intervention include transpyloric stenting, gastric electrical stimulation, and gastric per-oral endoscopic myotomy and in severe intractable gastroparesis, laparoscopic pyloroplasty or gastrectomy may be options.108
Diabetic diarrhoea
Diarrhoea occurs twice as frequently in diabetic patients and of course may be related to pancreatic exocrine insufficiency, bariatric surgery, and drugs such as metformin and GLP-1 agonists.109,110 Pharmacological therapies include antibiotics to eradicate bacterial overgrowth, somatostatin analogues, and selective serotonin 5-hydroxy tryptamine type 3 (HT3) receptor antagonists.111,112
Bladder dysfunction
Bladder dysfunction may occur in 50% of patients with diabetes due to urogenital autonomic neuropathy.113 Increased initiating threshold for the micturition reflex is followed by decreased detrusor activity and incomplete bladder emptying. The diagnosis should be based on urodynamic studies and the assessment of residual bladder volume. Treatment includes suprapubic pressure, intermittent self-catheterization, anticholinergic medication for detrusor hyperreflexia and parasympathomimetic medication to reduce detrusor contractility.114
Sudomotor dysfunction
A reduction or loss of distal sweating due to sympathetic denervation of the sweat glands is common115,116 and can precipitate a break in the skin, leading to foot ulceration. It can be assessed using neuropad®117–119 (Miro Verbandstoffe, Wiehl, Germany) or Sudoscan™120 Impeto Medical, Paris, France to risk stratify patients with DPN.121
Erectile dysfunction
Erectile dysfunction (ED) in patients with diabetes is three times more prevalent, may occur 10−15 years earlier and is less responsive to treatment, compared to patients without diabetes.122 ED is associated with a higher HbA1c, presence of metabolic syndrome, hypertension, dyslipidaemia, lower estimated glomerular filtration rate, higher albumin/creatinine ratio and more severe small-fibre neuropathy.123–125 Around 47% of women with diabetic neuropathy also have sexual dysfunction characterized by reduced sexual arousal, decreased lubrication and painful intercourse.126 Recent recommendations include active smoking cessation (improves ED by ~30%), testosterone replacement in those with testosterone deficiency, statins, phosphodiesterase type 5 inhibitors, intracavernosal and transurethral prostaglandins, and penile implants for more severe cases.127–129
Diabetic somatic and autonomic neuropathy have a significant impact on morbidity and mortality in the diabetic patient and yet remain woefully underdiagnosed and inadequately managed. Although there are currently no FDA-approved disease-modifying therapies, there is evidence that improvement in vascular risk factors alongside glycaemia may have a beneficial effect. Moderate relief of symptomatic, painful and autonomic neuropathy is possible, but requires early recognition and tailored intervention.
Acknowledgments
SA, MF, AK, HA, AAM, NH, SM, HB, HG, AK, GP, INP, UA contributed to the initial version of this article. RAM contributed and finalized the writing of the review.
Footnotes
Ethical Approval: Ethical approval was not required for this review.
Funding: This research received no specific grant from any funding agency in the public, commercial, or not-for-profit sectors.
Conflict of interest statement: The authors declare that there is no conflict of interest.
ORCID iD: Rayaz A Malik https://orcid.org/0000-0002-7188-8903
Contributor Information
Shazli Azmi, Institute of Cardiovascular Sciences, University of Manchester and Central Manchester NHS Foundation Trust, Manchester, UK.
Maryam Ferdousi, Institute of Cardiovascular Sciences, University of Manchester and Central Manchester NHS Foundation Trust, Manchester, UK.
Alise Kalteniece, Institute of Cardiovascular Sciences, University of Manchester and Central Manchester NHS Foundation Trust, Manchester, UK.
Hamad Al-Muhannadi, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.
Abdulrahman Al-Mohamedi, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.
Nebras H. Hadid, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar
Salah Mahmoud, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.
Harun A. Bhat, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar
Hoda Y. A. Gad, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar
Adnan Khan, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.
Georgios Ponirakis, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar.
Ioannis N. Petropoulos, Weill Cornell Medicine-Qatar, Qatar Foundation, Doha, Qatar
Uazman Alam, Department of Eye and Vision Science, University of Liverpool, Liverpool, UK.
Rayaz A. Malik, Weill Cornell Medicine-Qatar, Education City, Doha 24144, Qatar.
References
- 1. Pop-Busui R, Boulton AJ, Feldman EL, et al. Diabetic neuropathy: a position statement by the American Diabetes Association. Diabetes Care 2017; 40: 136–154. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2. Asghar O, Petropoulos IN, Alam U, et al. Corneal confocal microscopy detects neuropathy in subjects with impaired glucose tolerance. Diabetes Care 2014; 37: 2643–2646. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3. Azmi S, Ferdousi M, Petropoulos IN, et al. Corneal confocal microscopy identifies small-fiber neuropathy in subjects with impaired glucose tolerance who develop type 2 diabetes. Diabetes Care 2015; 38: 1502–1508. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 4. Malik RA. Which test for diagnosing early human diabetic neuropathy? Diabetes 2014; 63: 2206–2208. [DOI] [PubMed] [Google Scholar]
- 5. Martinelli-Boneschi F, Colombi M, Castori M, et al. COL6A5 variants in familial neuropathic chronic itch. Brain 2017; 140: 555–567. [DOI] [PubMed] [Google Scholar]
- 6. Rajabally YA, Stettner M, Kieseier BC, et al. CIDP and other inflammatory neuropathies in diabetes - diagnosis and management. Nat Rev Neurol 2017; 13: 599–611. [DOI] [PubMed] [Google Scholar]
- 7. Alam U, Riley DR, Jugdey RS, et al. Diabetic neuropathy and gait: a review. Diabetes Ther 2017; 8: 1253–1264. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8. Almurdhi MM, Brown SJ, Bowling FL, et al. Altered walking strategy and increased unsteadiness in participants with impaired glucose tolerance and type 2 diabetes relates to small-fibre neuropathy but not vitamin D deficiency. Diabet Med 2017; 34: 839–845. [DOI] [PubMed] [Google Scholar]
- 9. Almurdhi MM, Reeves ND, Bowling FL, et al. Reduced lower-limb muscle strength and volume in patients with type 2 diabetes in relation to neuropathy, intramuscular fat, and vitamin D levels. Diabetes Care 2016; 39: 441–447. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10. Yong TY, Khow KSF. Diabetic muscle infarction in end-stage renal disease: a scoping review on epidemiology, diagnosis and treatment. World J Nephrol 2018; 7: 58–64. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 11. Watanabe K, Hagura R, Akanuma Y, et al. characteristics of cranial nerve palsies in diabetic patients. Diabetes Res Clin Pract 1990; 10: 19–27. [DOI] [PubMed] [Google Scholar]
- 12. Calandruccio JH, Thompson NB. Carpal tunnel syndrome: making evidence-based treatment decisions. Orthop Clin North Am 2018; 49: 223–229. [DOI] [PubMed] [Google Scholar]
- 13. Mojaddidi MA, Ahmed MS, Ali R, et al. Molecular and pathological studies in the posterior interosseous nerve of diabetic and non-diabetic patients with carpal tunnel syndrome. Diabetologia 2014; 57: 1711–1719. [DOI] [PubMed] [Google Scholar]
- 14. Thomsen NO, Mojaddidi M, Malik RA, et al. Reduced myelinated nerve fibre and endoneurial capillary densities in the forearm of diabetic and non-diabetic patients with carpal tunnel syndrome. Acta Neuropathol 2009; 118: 785–791. [DOI] [PubMed] [Google Scholar]
- 15. Thomsen NOB, Andersson GS, Bjork J, et al. Neurophysiological recovery 5 years after carpal tunnel release in patients with diabetes. Muscle Nerve 2017; 56: E59–E64. [DOI] [PubMed] [Google Scholar]
- 16. Callaghan BC, Little AA, Feldman EL, et al. Enhanced glucose control for preventing and treating diabetic neuropathy. Cochrane Database Syst Rev 2012; 6: CD007543. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17. Malik RA. Why are there no good treatments for diabetic neuropathy? Lancet Diabetes Endocrinol 2014; 2: 607–609. [DOI] [PubMed] [Google Scholar]
- 18. Malik RA. Wherefore art thou, o treatment for diabetic neuropathy? Int Rev Neurobiol 2016; 127: 287–317. [DOI] [PubMed] [Google Scholar]
- 19. Tesfaye S, Chaturvedi N, Eaton SE, et al. Vascular risk factors and diabetic neuropathy. N Engl J Med 2005; 352: 341–350. [DOI] [PubMed] [Google Scholar]
- 20. Oellgaard J, Gaede P, Rossing P, et al. Reduced risk of heart failure with intensified multifactorial intervention in individuals with type 2 diabetes and microalbuminuria: 21 years of follow-up in the randomised STENO-2 study. Diabetologia 2018; 61: 1724–1733. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21. Gaede P, Lund-Andersen H, Parving HH, et al. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med 2008; 358: 580–591. [DOI] [PubMed] [Google Scholar]
- 22. Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003; 348: 383–393. [DOI] [PubMed] [Google Scholar]
- 23. Ishibashi F, Taniguchi M, Kosaka A, et al. Improvement in neuropathy outcomes with normalizing HbA1c in patients with type 2 diabetes. Diabetes Care. Epub ahead of print 19 November 2018. DOI: 10.2337/dc18-1560. [DOI] [PubMed] [Google Scholar]
- 24. Tavakoli M, Kallinikos P, Iqbal A, et al. Corneal confocal microscopy detects improvement in corneal nerve morphology with an improvement in risk factors for diabetic neuropathy. Diabet Med 2011; 28: 1261–1267. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 25. Smith AG, Russell J, Feldman EL, et al. Lifestyle intervention for pre-diabetic neuropathy. Diabetes Care 2006; 29: 1294–1299. [DOI] [PubMed] [Google Scholar]
- 26. Malik RA, Williamson S, Abbott C, et al. Effect of angiotensin-converting-enzyme (ACE) inhibitor trandolapril on human diabetic neuropathy: randomised double-blind controlled trial. Lancet 1998; 352: 1978–1981. [DOI] [PubMed] [Google Scholar]
- 27. Ruggenenti P, Lauria G, Iliev IP, et al. Effects of manidipine and delapril in hypertensive patients with type 2 diabetes mellitus: the delapril and manidipine for nephroprotection in diabetes (DEMAND) randomized clinical trial. Hypertension 2011; 58: 776–783. [DOI] [PubMed] [Google Scholar]
- 28. Nielsen SF, Nordestgaard BG. Statin use before diabetes diagnosis and risk of microvascular disease: a nationwide nested matched study. Lancet Diabetes Endocrinol 2014; 2: 894–900. [DOI] [PubMed] [Google Scholar]
- 29. Davis TM, Yeap BB, Davis WA, et al. Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study. Diabetologia 2008; 51: 562–566. [DOI] [PubMed] [Google Scholar]
- 30. Nassaji M, Ghorbani R, Saboori Shkofte H. Previous atorvastatin treatment and risk of diabetic foot infection in adult patients: a case-control study. Wounds 2017; 29: 196–201. [PubMed] [Google Scholar]
- 31. Rajamani K, Colman PG, Li LP, et al. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. Lancet 2009; 373: 1780–1788. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32. Sohn MW, Meadows JL, Oh EH, et al. Statin use and lower extremity amputation risk in nonelderly diabetic patients. J Vasc Surg 2013; 58: 1578–1585.e1. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 33. Fox JD, Baquerizo-Nole KL, Macquhae F, et al. Statins may be associated with six-week diabetic foot ulcer healing. Wound Repair Regen 2016; 24: 454–457. [DOI] [PubMed] [Google Scholar]
- 34. Dhatariya K, Bain SC, Buse JB, et al. The impact of liraglutide on diabetes-related foot ulceration and associated complications in patients with type 2 diabetes at high risk for cardiovascular events: results from the LEADER trial. Diabetes Care 2018; 41: 2229–2235. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35. Moustafa PE. Liraglutide ameliorated peripheral neuropathy in diabetic rats: involvement of oxidative stress, inflammation and extracellular matrix remodeling. Diabetes Metab Res Rev 2018; 146: 173–185. [DOI] [PubMed] [Google Scholar]
- 36. Sango K, Utsunomiya K. Efficacy of glucagon-like peptide-1 mimetics for neural regeneration. Neural Regen Res 2015; 10: 1723–1724. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37. Tsukamoto M, Niimi N, Sango K, et al. Neurotrophic and neuroprotective properties of exendin-4 in adult rat dorsal root ganglion neurons: involvement of insulin and RhoA. Histochem Cell Biol 2015; 144: 249–259. [DOI] [PubMed] [Google Scholar]
- 38. Sorensen L, Molyneaux L, Yue DK. The relationship among pain, sensory loss, and small nerve fibers in diabetes. Diabetes Care 2006; 29: 883–887. [DOI] [PubMed] [Google Scholar]
- 39. Vlckova-Moravcova E, Bednarik J, Belobradkova J, et al. Small-fibre involvement in diabetic patients with neuropathic foot pain. Diabet Med 2008; 25: 692–699. [DOI] [PubMed] [Google Scholar]
- 40. Quattrini C, Tavakoli M, Jeziorska M, et al. Surrogate markers of small fiber damage in human diabetic neuropathy. Diabetes 2007; 56: 2148–2154. [DOI] [PubMed] [Google Scholar]
- 41. Van Acker K, Bouhassira D, De Bacquer D, et al. Prevalence and impact on quality of life of peripheral neuropathy with or without neuropathic pain in type 1 and type 2 diabetic patients attending hospital outpatients clinics. Diabetes Metab 2009; 35: 206–213. [DOI] [PubMed] [Google Scholar]
- 42. Bohlega S, Alsaadi T, Amir A, et al. Guidelines for the pharmacological treatment of peripheral neuropathic pain: expert panel recommendations for the middle East region. J Int Med Res 2010; 38: 295–317. [DOI] [PubMed] [Google Scholar]
- 43. DaCosta DiBonaventura M, Cappelleri JC, Joshi AV. A longitudinal assessment of painful diabetic peripheral neuropathy on health status, productivity, and health care utilization and cost. Pain Med 2011; 12: 118–126. [DOI] [PubMed] [Google Scholar]
- 44. Abbott CA, Malik RA, van Ross ER, et al. Prevalence and characteristics of painful diabetic neuropathy in a large community-based diabetic population in the U.K. Diabetes Care 2011; 34: 2220–2224. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45. Jambart S, Ammache Z, Haddad F, et al. Prevalence of painful diabetic peripheral neuropathy among patients with diabetes mellitus in the Middle East region. J Int Med Res 2011; 39: 366–377. [DOI] [PubMed] [Google Scholar]
- 46. Davies M, Brophy S, Williams R, et al. The prevalence, severity, and impact of painful diabetic peripheral neuropathy in type 2 diabetes. Diabetes Care 2006; 29: 1518–1522. [DOI] [PubMed] [Google Scholar]
- 47. Ziegler D, Rathmann W, Meisinger C, et al. Prevalence and risk factors of neuropathic pain in survivors of myocardial infarction with pre-diabetes and diabetes. The KORA Myocardial Infarction Registry. Eur J Pain 2009; 13: 582–587. [DOI] [PubMed] [Google Scholar]
- 48. Jacovides A, Bogoshi M, Distiller LA, et al. An epidemiological study to assess the prevalence of diabetic peripheral neuropathic pain among adults with diabetes attending private and institutional outpatient clinics in South Africa. J Int Med Res 2014; 42: 1018–1028. [DOI] [PubMed] [Google Scholar]
- 49. Sadosky A, McDermott AM, Brandenburg NA, et al. A review of the epidemiology of painful diabetic peripheral neuropathy, postherpetic neuralgia, and less commonly studied neuropathic pain conditions. Pain Pract 2008; 8: 45–56. [DOI] [PubMed] [Google Scholar]
- 50. Abbott CA, Chaturvedi N, Malik RA, et al. Explanations for the lower rates of diabetic neuropathy in Indian Asians versus Europeans. Diabetes Care 2010; 33: 1325–1330. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 51. Fadavi H, Tavakoli M, Foden P, et al. Explanations for less small fibre neuropathy in south Asian versus European subjects with type 2 diabetes in the UK. Diabetes Metab Res Rev 2018; 34: e3044. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 52. Spallone V, Morganti R, D’Amato C, et al. Validation of DN4 as a screening tool for neuropathic pain in painful diabetic polyneuropathy. Diabet Med 2012; 29: 578–585. [DOI] [PubMed] [Google Scholar]
- 53. Bennett M. The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs. Pain 2001; 92: 147–157. [DOI] [PubMed] [Google Scholar]
- 54. Krause SJ, Backonja MM. Development of a neuropathic pain questionnaire. Clin J Pain 2003; 19: 306–314. [DOI] [PubMed] [Google Scholar]
- 55. Daousi C, MacFarlane IA, Woodward A, et al. Chronic painful peripheral neuropathy in an urban community: a controlled comparison of people with and without diabetes. Diabet Med 2004; 21: 976–982. [DOI] [PubMed] [Google Scholar]
- 56. Ziegler D, Landgraf R, Lobmann R, et al. Painful and painless neuropathies are distinct and largely undiagnosed entities in subjects participating in an educational initiative (PROTECT study). Diabetes Res Clin Pract 2018; 139: 147–154. [DOI] [PubMed] [Google Scholar]
- 57. Malik RA, Aldinc E, Chan SP, et al. Perceptions of painful diabetic peripheral neuropathy in South-East Asia: results from patient and physician surveys. Adv Ther 2017; 34: 1426–1437. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 58. Aslam A, Singh J, Rajbhandari S. Prevalence of painful diabetic neuropathy using the self-completed Leeds assessment of neuropathic symptoms and signs questionnaire in a population with diabetes. Can J Diabetes 2015; 39: 285–295. [DOI] [PubMed] [Google Scholar]
- 59. Harris M, Eastman R, Cowie C. Symptoms of sensory neuropathy in adults with NIDDM in the U.S. population. Diabetes Care 1993; 16: 1446–1452. [DOI] [PubMed] [Google Scholar]
- 60. Smith AG, Singleton JR. Impaired glucose tolerance and neuropathy. Neurologist 2008; 14: 23–29. [DOI] [PubMed] [Google Scholar]
- 61. Alam U, Arul-Devah V, Javed S, et al. Vitamin D and diabetic complications: true or false prophet? Diabetes Ther 2016; 7: 11–26. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62. Shillo P, Selvarajah D, Greig M, et al. Reduced vitamin D levels in painful diabetic peripheral neuropathy. Epub ahead of print 20 September 2018. DOI: 10.1111/dme.13798. [DOI] [PubMed] [Google Scholar]
- 63. Gibbons CH, Freeman R. Treatment-induced neuropathy of diabetes: an acute, iatrogenic complication of diabetes. Brain 2015; 138: 43–52. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64. Spallone V. Might genetics play a role in understanding and treating diabetic polyneuropathy? Diabetes Metab Res Rev 2017; 33. [DOI] [PubMed] [Google Scholar]
- 65. Wadhawan S, Pant S, Golhar R, et al. NaV channel variants in patients with painful and nonpainful peripheral neuropathy. Neurol Genet 2017; 3: e207. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66. Vollert J, Maier C, Attal N, et al. Stratifying patients with peripheral neuropathic pain based on sensory profiles: algorithm and sample size recommendations. Pain 2017; 158: 1446–1455. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 67. Demant DT, Lund K, Vollert J, et al. The effect of oxcarbazepine in peripheral neuropathic pain depends on pain phenotype: a randomised, double-blind, placebo-controlled phenotype-stratified study. Pain 2014; 155: 2263–2273. [DOI] [PubMed] [Google Scholar]
- 68. Marshall AG, Lee-Kubli C, Azmi S, et al. Spinal disinhibition in experimental and clinical painful diabetic neuropathy. Diabetes 2017; 66: 1380–1390. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 69. Botney M, Fields HL. Amitriptyline potentiates morphine analgesia by a direct action on the central nervous system. Ann Neurol 1983; 13: 160–164. [DOI] [PubMed] [Google Scholar]
- 70. Benbouzid M, Gaveriaux-Ruff C, Yalcin I, et al. Delta-opioid receptors are critical for tricyclic antidepressant treatment of neuropathic allodynia. Biol Psychiatry 2008; 63: 633–636. [DOI] [PubMed] [Google Scholar]
- 71. De Gandarias JM, Echevarria E, Acebes I, et al. Effects of imipramine administration on mu-opioid receptor immunostaining in the rat forebrain. Arzneimittelforschung 1998; 48: 717–719. [PubMed] [Google Scholar]
- 72. Moore RA, Derry S, Aldington D, et al. Amitriptyline for neuropathic pain in adults. Cochrane Database Syst Rev 2015; 7: CD008242. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 73. Hossain SM, Hussain SM, Ekram AR. Duloxetine in painful diabetic neuropathy: a systematic review. Clin J Pain 2016; 32: 1005–1010. [DOI] [PubMed] [Google Scholar]
- 74. Lunn MP, Hughes RA, Wiffen PJ. Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia. Cochrane Database Syst Rev 2014; 3: CD007115. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 75. Wiffen PJ, Derry S, Bell RF, et al. Gabapentin for chronic neuropathic pain in adults. Cochrane Database Syst Rev 2017; 6: CD007938. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 76. Lesser H, Sharma U, LaMoreaux L, et al. Pregabalin relieves symptoms of painful diabetic neuropathy: a randomized controlled trial Neurology 2004; 63: 2104–2110. [DOI] [PubMed] [Google Scholar]
- 77. Rosenstock J, Tuchman M, LaMoreaux L, et al. Pregabalin for the treatment of painful diabetic peripheral neuropathy: a double-blind, placebo-controlled trial. Pain 2004; 110: 628–638. [DOI] [PubMed] [Google Scholar]
- 78. Arezzo JC, Rosenstock J, Lamoreaux L, et al. Efficacy and safety of pregabalin 600 mg/d for treating painful diabetic peripheral neuropathy: a double-blind placebo-controlled trial. BMC Neurol 2008; 8: 33. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 79. Javed S, Alam U, Malik RA. Mirogabalin and emerging therapies for diabetic neuropathy. J Pain Res 2018; 11: 1559–1566. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 80. Merante D, Rosenstock J, Sharma U, et al. Efficacy of mirogabalin (DS-5565) on patient-reported pain and sleep interference in patients with diabetic neuropathic pain: secondary outcomes of a phase II proof-of-concept study. Pain Med 2017; 18: 2198–2207. [DOI] [PubMed] [Google Scholar]
- 81. Vinik A, Rosenstock J, Sharma U, et al. Efficacy and safety of mirogabalin (DS-5565) for the treatment of diabetic peripheral neuropathic pain: a randomized, double-blind, placebo- and active comparator-controlled, adaptive proof-of-concept phase 2 study. Diabetes Care 2014; 37: 3253–3261. [DOI] [PubMed] [Google Scholar]
- 82. Duehmke RM, Derry S, Wiffen PJ, et al. Tramadol for neuropathic pain in adults. Cochrane Database Syst Rev 2017; 15: CD003726. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 83. Vinik AI, Shapiro DY, Rauschkolb C, et al. A randomized withdrawal, placebo-controlled study evaluating the efficacy and tolerability of tapentadol extended release in patients with chronic painful diabetic peripheral neuropathy. Diabetes Care 2014; 37: 2302–2309. [DOI] [PubMed] [Google Scholar]
- 84. Niesters M, Proto PL, Aarts L, et al. Tapentadol potentiates descending pain inhibition in chronic pain patients with diabetic polyneuropathy. Br J Anaesth 2014; 113: 148–156. [DOI] [PubMed] [Google Scholar]
- 85. Schwartz S, Etropolski MS, Shapiro DY, et al. A pooled analysis evaluating the efficacy and tolerability of tapentadol extended release for chronic, painful diabetic peripheral neuropathy. Clin Drug Investig 2015; 35: 95–108. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 86. Vadivelu N, Kai A, Maslin B, et al. Tapentadol extended release in the management of peripheral diabetic neuropathic pain. Ther Clin Risk Manag 2015; 11: 95–105. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 87. Tesfaye S, Wilhelm S, Lledo A, et al. Duloxetine and pregabalin: high-dose monotherapy or their combination? The “COMBO-DN study”–a multinational, randomized, double-blind, parallel-group study in patients with diabetic peripheral neuropathic pain. Pain 2013; 154: 2616–2625. [DOI] [PubMed] [Google Scholar]
- 88. Bouhassira D, Wilhelm S, Schacht A, et al. Neuropathic pain phenotyping as a predictor of treatment response in painful diabetic neuropathy: data from the randomized, double-blind, COMBO-DN study. Pain 2014; 155: 2171–2179. [DOI] [PubMed] [Google Scholar]
- 89. Boyle J, Eriksson MEV, Gribble L, et al. Randomized, placebo-controlled comparison of amitriptyline, duloxetine, and pregabalin in patients with chronic diabetic peripheral neuropathic pain: impact on pain, polysomnographic sleep, daytime functioning, and quality of life. Diabetes Care 2012; 35: 2451–2458. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 90. Basit A, Basit KA, Fawwad A, et al. Vitamin D for the treatment of painful diabetic neuropathy. BMJ Open Diabetes Res Care 2016; 4: e000148. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 91. Alam U, Fawwad A. Improvement in neuropathy specific quality of life in patients with diabetes after vitamin D supplementation. J Diabetes Res 2017; 2017: 7928083. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 92. Soedamah-Muthu SS, Chaturvedi N, Witte DR, et al. Relationship between risk factors and mortality in type 1 diabetic patients in Europe: the EURODIAB Prospective Complications Study (PCS). Diabetes Care 2008; 31: 1360–1366. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 93. Pop-Busui R, Evans GW, Gerstein HC, et al. Effects of cardiac autonomic dysfunction on mortality risk in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. Diabetes Care 2010; 33: 1578–1584. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 94. Low PA, Benrud-Larson LM, Sletten DM, et al. Autonomic symptoms and diabetic neuropathy: a population-based study. Diabetes Care 2004; 27: 2942–2947. [DOI] [PubMed] [Google Scholar]
- 95. Suarez GA, Opfer-Gehrking TL, Offord KP, et al. The autonomic symptom profile: a new instrument to assess autonomic symptoms. Neurology 1999; 52: 523–528. [DOI] [PubMed] [Google Scholar]
- 96. Tesfaye S, Boulton AJ, Dyck PJ, et al. Diabetic neuropathies: update on definitions, diagnostic criteria, estimation of severity, and treatments. Diabetes Care 2010; 33: 2285–2293. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 97. Martin CL, Albers JW, Pop-Busui R, et al. Neuropathy and related findings in the diabetes control and complications trial/epidemiology of diabetes interventions and complications study. Diabetes Care 2014; 37: 31–38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 98. Charles M, Fleischer J, Witte DR, et al. Impact of early detection and treatment of diabetes on the 6-year prevalence of cardiac autonomic neuropathy in people with screen-detected diabetes: ADDITION-Denmark, a cluster-randomised study. Diabetologia 2013; 56: 101–108. [DOI] [PubMed] [Google Scholar]
- 99. Charles M, Ejskjaer N, Witte DR, et al. Prevalence of neuropathy and peripheral arterial disease and the impact of treatment in people with screen-detected type 2 diabetes: the ADDITION-Denmark study. Diabetes Care 2011; 34: 2244–2249. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 100. Ziegler D, Schatz H, Conrad F, et al. Effects of treatment with the antioxidant alpha-lipoic acid on cardiac autonomic neuropathy in NIDDM patients. A 4-month randomized controlled multicenter trial (DEKAN Study). Deutsche Kardiale Autonome Neuropathie. Diabetes Care 1997; 20: 369–373. [DOI] [PubMed] [Google Scholar]
- 101. Pop-Busui R, Stevens MJ, Raffel DM, et al. Effects of triple antioxidant therapy on measures of cardiovascular autonomic neuropathy and on myocardial blood flow in type 1 diabetes: a randomised controlled trial. Diabetologia 2013; 56: 1835–1844. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 102. Pop-Busui R. Cardiac autonomic neuropathy in diabetes: a clinical perspective. Diabetes Care 2010; 33: 434–441. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 103. Freeman R, Abuzinadah AR, Gibbons C, et al. Orthostatic hypotension: JACC state-of-the-art review. J Am Coll Cardiol 2018; 72: 1294–1309. [DOI] [PubMed] [Google Scholar]
- 104. Gibbons CH, Schmidt P, Biaggioni I, et al. The recommendations of a consensus panel for the screening, diagnosis, and treatment of neurogenic orthostatic hypotension and associated supine hypertension. J Neurol 2017; 264: 1567–1582. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 105. Freeman R. Clinical practice. Neurogenic orthostatic hypotension. N Engl J Med 2008; 358: 615–624. [DOI] [PubMed] [Google Scholar]
- 106. Kaufmann H. Droxidopa for symptomatic neurogenic orthostatic hypotension: what can we learn? Clin Auton Res 2017; 27: 1–3. [DOI] [PubMed] [Google Scholar]
- 107. Parkman HP, Hasler WL, Fisher RS, et al. American Gastroenterological Association technical review on the diagnosis and treatment of gastroparesis. Gastroenterology 2004; 127: 1592–1622. [DOI] [PubMed] [Google Scholar]
- 108. Kumar M, Chapman A, Javed S, et al. The investigation and treatment of diabetic gastroparesis. Clin Ther 2018; 40: 850–861. [DOI] [PubMed] [Google Scholar]
- 109. Sommers T, Mitsuhashi S, Singh P, et al. Prevalence of chronic constipation and chronic diarrhea in diabetic individuals in the United States. Am J Gastroenterol. 2019; 114: 135-142. [DOI] [PubMed] [Google Scholar]
- 110. Borbely YM, Osterwalder A, Kroll D, et al. Diarrhea after bariatric procedures: diagnosis and therapy. World J Gastroenterol 2017; 23: 4689–4700. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 111. Murao S, Hosokawa H. Serotonin 5-HT3 receptor antagonist for treatment of severe diabetic diarrhea. Diabetes Care 2010; 33: e38. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 112. Ogbonnaya KI, Arem R. Diabetic diarrhea. Pathophysiology, diagnosis, and management. Arch Intern Med 1990; 150: 262–267. [DOI] [PubMed] [Google Scholar]
- 113. Freeman R. Autonomic peripheral neuropathy. Lancet 2005; 365: 1259–1270. [DOI] [PubMed] [Google Scholar]
- 114. Yuan Z, Tang Z, He C, et al. Diabetic cystopathy: a review. J Diabetes 2015; 7: 442–447. [DOI] [PubMed] [Google Scholar]
- 115. Gibbons CH, Illigens BM, Wang N, et al. Quantification of sweat gland innervation: a clinical-pathologic correlation. Neurology 2009; 72: 1479–1486. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 116. Gibbons CH, Illigens BM, Wang N, et al. Quantification of sudomotor innervation: a comparison of three methods. Muscle Nerve 2010; 42: 112–119. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 117. Ponirakis G, Fadavi H, Petropoulos IN, et al. Automated quantification of neuropad improves its diagnostic ability in patients with diabetic neuropathy. J Diabetes Res 2015; 2015: 847854. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 118. Ponirakis G, Petropoulos IN, Fadavi H, et al. The diagnostic accuracy of neuropad for assessing large and small fibre diabetic neuropathy. Diabet Med 2014; 31: 1673–1680. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 119. Quattrini C, Jeziorska M, Tavakoli M, et al. The neuropad test: a visual indicator test for human diabetic neuropathy. Diabetologia 2008; 51: 1046–1050. [DOI] [PubMed] [Google Scholar]
- 120. Krieger SM, Reimann M, Haase R, et al. Sudomotor testing of diabetes polyneuropathy. Front Neurol 2018; 9: 803. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 121. Tsapas A, Liakos A, Paschos P, et al. A simple plaster for screening for diabetic neuropathy: a diagnostic test accuracy systematic review and meta-analysis. Metabolism 2014; 63: 584–592. [DOI] [PubMed] [Google Scholar]
- 122. Feldman HA, Goldstein I, Hatzichristou DG, et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61. [DOI] [PubMed] [Google Scholar]
- 123. Azmi S, Ferdousi M, Alam U, et al. Small-fibre neuropathy in men with type 1 diabetes and erectile dysfunction: a cross-sectional study. Diabetologia 2017; 60: 1094–1101. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 124. Giugliano F, Maiorino M, Bellastella G, et al. Determinants of erectile dysfunction in type 2 diabetes. Int J Impot Res 2010; 22: 204. [DOI] [PubMed] [Google Scholar]
- 125. Van Den Eeden SK, Sarma AV, Rutledge BN, et al. Effect of intensive glycemic control and diabetes complications on lower urinary tract symptoms in men with type 1 diabetes: Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) study. Diabetes Care 2009; 32: 664–670. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 126. Enzlin P, Mathieu C, Van den Bruel A, et al. Sexual dysfunction in women with type 1 diabetes: a controlled study. Diabetes Care 2002; 25: 672–677. [DOI] [PubMed] [Google Scholar]
- 127. Hackett G, Kirby M, Wylie K, et al. British Society for Sexual Medicine guidelines on the management of erectile dysfunction in men-2017. J Sex Med 2018; 15: 430–457. [DOI] [PubMed] [Google Scholar]
- 128. Mulhall JP, Giraldi A, Hackett G, et al. The 2018 revision to the process of care model for evaluation of erectile dysfunction. J Sex Med 2018; 15: 1280–1292. [DOI] [PubMed] [Google Scholar]
- 129. Mulhall JP, Giraldi A, Hackett G, et al. The 2018 revision to the process of care model for management of erectile dysfunction. J Sex Med 2018; 15: 1434–1445. [DOI] [PubMed] [Google Scholar]